{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T02:53:01Z","timestamp":1717555981998},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,28]],"date-time":"2010-11-28T00:00:00Z","timestamp":1290902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s00345-010-0617-4","type":"journal-article","created":{"date-parts":[[2010,11,27]],"date-time":"2010-11-27T05:15:02Z","timestamp":1290834902000},"page":"59-71","source":"Crossref","is-referenced-by-count":19,"title":["Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Alon Z.","family":"Weizer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,28]]},"reference":[{"key":"617_CR1","doi-asserted-by":"crossref","unstructured":"Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60(5):277\u2013300","DOI":"10.3322\/caac.20073"},{"key":"617_CR2","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964\u20131970","DOI":"10.1016\/S0022-5347(05)64273-5"},{"key":"617_CR3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","volume":"56","author":"BW Rhijn van","year":"2009","unstructured":"van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430\u2013442","journal-title":"Eur Urol"},{"key":"617_CR4","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2165\/00019053-200321180-00003","volume":"21","author":"MF Botteman","year":"2003","unstructured":"Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21:1315\u20131330","journal-title":"Pharmacoeconomics"},{"key":"617_CR5","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","volume":"178","author":"MC Hall","year":"2007","unstructured":"Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314\u20132330","journal-title":"J Urol"},{"key":"617_CR6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","volume":"54","author":"M Babjuk","year":"2008","unstructured":"Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J (2008) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54:303\u2013314","journal-title":"Eur Urol"},{"key":"617_CR7","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124\u20131129","journal-title":"J Urol"},{"key":"617_CR8","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","volume":"13","author":"HW Herr","year":"1995","unstructured":"Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF Jr, Oettgen HF (1995) Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13:1404\u20131408","journal-title":"J Clin Oncol"},{"key":"617_CR9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1442-2042.2001.00355.x","volume":"8","author":"H Sekine","year":"2001","unstructured":"Sekine H, Ohya K, Kojima SI, Igarashi K, Fukui I (2001) Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. Int J Urol 8:483\u2013486","journal-title":"Int J Urol"},{"key":"617_CR10","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","volume":"325","author":"DL Lamm","year":"1991","unstructured":"Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325:1205\u20131209","journal-title":"N Engl J Med"},{"key":"617_CR11","doi-asserted-by":"crossref","unstructured":"Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M (2000) Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer. Cochrane Database Syst Rev: CD001986","DOI":"10.1002\/14651858.CD001986"},{"key":"617_CR12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/canjclin.46.2.93","volume":"46","author":"DL Lamm","year":"1996","unstructured":"Lamm DL, Torti FM (1996) Bladder cancer, 1996. CA Cancer J Clin 46:93\u2013112","journal-title":"CA Cancer J Clin"},{"key":"617_CR13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","volume":"5","author":"RA Badalament","year":"1987","unstructured":"Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF Jr, Fair WR, Oettgen HF (1987) A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 5:441\u2013449","journal-title":"J Clin Oncol"},{"key":"617_CR14","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","volume":"171","author":"RJ Sylvester","year":"2004","unstructured":"Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186\u20132190","journal-title":"J Urol"},{"key":"617_CR15","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1097\/01.ju.0000181799.81119.fc","volume":"174","author":"HW Herr","year":"2005","unstructured":"Herr HW (2005) Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 174:2134\u20132137","journal-title":"J Urol"},{"key":"617_CR16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jnci\/djp039","volume":"101","author":"BK Hollenbeck","year":"2009","unstructured":"Hollenbeck BK, Ye Z, Dunn RL, Montie JE, Birkmeyer JD (2009) Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst 101:571\u2013580","journal-title":"J Natl Cancer Inst"},{"key":"617_CR17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","volume":"33","author":"M Takashi","year":"2002","unstructured":"Takashi M, Wakai K, Hattori T, Furuhashi K, Ono Y, Ohshima S, Ohno Y (2002) Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int Urol Nephrol 33:41\u201347","journal-title":"Int Urol Nephrol"},{"key":"617_CR18","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0022-5347(01)64825-0","volume":"157","author":"H Ovesen","year":"1997","unstructured":"Ovesen H, Horn T, Steven K (1997) Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J Urol 157:1655\u20131659","journal-title":"J Urol"},{"key":"617_CR19","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","volume":"53","author":"J Fernandez-Gomez","year":"2008","unstructured":"Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J (2008) Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53:992\u20131001","journal-title":"Eur Urol"},{"key":"617_CR20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.juro.2010.03.134","volume":"184","author":"DC Chade","year":"2010","unstructured":"Chade DC, Shariat SF, Adamy A, Bochner BH, Donat SM, Herr HW, Dalbagni G (2010) Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol 184:464\u2013469","journal-title":"J Urol"},{"key":"617_CR21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","volume":"93","author":"JL Au","year":"2001","unstructured":"Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93:597\u2013604","journal-title":"J Natl Cancer Inst"},{"key":"617_CR22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.juro.2010.03.032","volume":"184","author":"DC Chade","year":"2010","unstructured":"Chade DC, Shariat SF, Godoy G, Savage CJ, Cronin AM, Bochner BH, Donat SM, Herr HW, Dalbagni G (2010) Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol 184:74\u201380","journal-title":"J Urol"},{"key":"617_CR23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","volume":"173","author":"TM Reijke de","year":"2005","unstructured":"de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P (2005) Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer\u2013Genito-Urinary Group Phase III Trial (30906). J Urol 173:405\u2013409","journal-title":"J Urol"},{"key":"617_CR24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00345-009-0389-x","volume":"27","author":"SM Di Stasi","year":"2009","unstructured":"Di Stasi SM, Riedl C (2009) Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J Urol 27:325\u2013330","journal-title":"World J Urol"},{"key":"617_CR25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.urolonc.2007.12.011","volume":"27","author":"ON Gofrit","year":"2009","unstructured":"Gofrit ON, Pode D, Pizov G, Zorn KC, Katz R, Duvdevani M, Shapiro A (2009) The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guerin immunotherapy. Urol Oncol 27:258\u2013262","journal-title":"Urol Oncol"},{"key":"617_CR26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.ju.0000070437.14275.e0","volume":"170","author":"MO Grimm","year":"2003","unstructured":"Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA (2003) Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 170:433\u2013437","journal-title":"J Urol"},{"key":"617_CR27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","volume":"40","author":"G Jakse","year":"2001","unstructured":"Jakse G, Hall R, Bono A, Holtl W, Carpentier P, Spaander JP, van der Meijden AP, Sylvester R (2001) Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 40:144\u2013150","journal-title":"Eur Urol"},{"key":"617_CR28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","volume":"43","author":"E Kaasinen","year":"2003","unstructured":"Kaasinen E, Wijkstrom H, Malmstrom PU, Hellsten S, Duchek M, Mestad O, Rintala E (2003) Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol 43:637\u2013645","journal-title":"Eur Urol"},{"key":"617_CR29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-5347(05)67974-8","volume":"163","author":"A Losa","year":"2000","unstructured":"Losa A, Hurle R, Lembo A (2000) Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 163:68\u201371","journal-title":"J Urol"},{"key":"617_CR30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0090-4295(98)00369-0","volume":"52","author":"J Baniel","year":"1998","unstructured":"Baniel J, Grauss D, Engelstein D, Sella A (1998) Intravesical bacillus Calmette-Guerin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 52:785\u2013789","journal-title":"Urology"},{"key":"617_CR31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0090-4295(99)00591-9","volume":"55","author":"M Brake","year":"2000","unstructured":"Brake M, Loertzer H, Horsch R, Keller H (2000) Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer. Urology 55:673\u2013678","journal-title":"Urology"},{"key":"617_CR32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","volume":"57","author":"M Duchek","year":"2010","unstructured":"Duchek M, Johansson R, Jahnson S, Mestad O, Hellstrom P, Hellsten S, Malmstrom PU (2010) Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 57:25\u201331","journal-title":"Eur Urol"},{"key":"617_CR33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000087162","volume":"75","author":"B Gunlusoy","year":"2005","unstructured":"Gunlusoy B, Degirmenci T, Arslan M, Nergiz N, Minareci S, Ayder AR (2005) Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guerin. Urol Int 75:107\u2013113","journal-title":"Urol Int"},{"key":"617_CR34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0090-4295(99)00116-8","volume":"54","author":"R Hurle","year":"1999","unstructured":"Hurle R, Losa A, Manzetti A, Lembo A (1999) Intravesical bacille Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54:258\u2013263","journal-title":"Urology"},{"key":"617_CR35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1442-2042.2008.02235.x","volume":"16","author":"E Kikuchi","year":"2009","unstructured":"Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T (2009) Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999\u20132001 report from the Japanese Urological Association. Int J Urol 16:279\u2013286","journal-title":"Int J Urol"},{"key":"617_CR36","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1464-410X.2002.02969.x","volume":"90","author":"JN Kulkarni","year":"2002","unstructured":"Kulkarni JN, Gupta R (2002) Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guerin (Danish 1331 strain). BJU Int 90:554\u2013557","journal-title":"BJU Int"},{"key":"617_CR37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.urology.2006.09.019","volume":"69","author":"D Margel","year":"2007","unstructured":"Margel D, Tal R, Golan S, Kedar D, Engelstein D, Baniel J (2007) Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guerin immunotherapy. Urology 69:78\u201382","journal-title":"Urology"},{"key":"617_CR38","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","volume":"174","author":"JA Martinez-Pineiro","year":"2005","unstructured":"Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, Rodriguez RH, Gomez JM, Martin MG, Molina JR, Collado AG, Flores N, Isorna S (2005) Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174:1242\u20131247","journal-title":"J Urol"},{"key":"617_CR39","first-page":"223","volume":"22","author":"V Pansadoro","year":"2003","unstructured":"Pansadoro V, Emiliozzi P, depaula F, Scarpone P, Pizzo M, Federico G, Martini M, Pansadoro A, Sternberg CN (2003) High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG). J Exp Clin Cancer Res 22:223\u2013227","journal-title":"J Exp Clin Cancer Res"},{"key":"617_CR40","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0302-2838(02)00173-2","volume":"41","author":"JJ Patard","year":"2002","unstructured":"Patard JJ, Rodriguez A, Leray E, Rioux-Leclercq N, Guille F, Lobel B (2002) Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 41:635\u2013641","journal-title":"Eur Urol"},{"key":"617_CR41","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1097\/01.ju.0000066840.42991.4a","volume":"169","author":"M Peyromaure","year":"2003","unstructured":"Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M (2003) Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol 169:2110\u20132112","journal-title":"J Urol"},{"key":"617_CR42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","volume":"169","author":"O Shahin","year":"2003","unstructured":"Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE (2003) A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169:96\u2013100","journal-title":"J Urol"},{"key":"617_CR43","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.urology.2007.11.080","volume":"71","author":"T Yoneyama","year":"2008","unstructured":"Yoneyama T, Ohyama C, Imai A, Ishimura H, Hagisawa S, Iwabuchi I, Mori K, Kamimura N, Koie T, Yamato T (2008) Low-dose instillation therapy with bacille Calmette-Guerin Tokyo 172 strain after transurethral resection: historical cohort study. Urology 71:1161\u20131165","journal-title":"Urology"},{"key":"617_CR44","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000020018","volume":"36","author":"E Zungri","year":"1999","unstructured":"Zungri E, Martinez L, Da Silva EA, Pesqueira D, de la Fuente Buceta A, Pereiro B (1999) T1 GIII bladder cancer. Management with transurethral resection only. Eur Urol 36:380\u2013384","journal-title":"Eur Urol"},{"key":"617_CR45","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/cncr.23627","volume":"113","author":"M Decobert","year":"2008","unstructured":"Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L (2008) Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Cancer 113:710\u2013716","journal-title":"Cancer"},{"key":"617_CR46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"SM Di Stasi","year":"2006","unstructured":"Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, Attisani F, De Carolis A, Capelli G, Vespasiani G (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7:43\u201351","journal-title":"Lancet Oncol"},{"key":"617_CR47","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000030333","volume":"61","author":"R Hurle","year":"1998","unstructured":"Hurle R, Manzetti A, Losa A, Micheli E, Ranieri A, Chinaglia D, Lembo A (1998) Intravesical instillation of mitomycin-C in 242 patients with superficial bladder cancer at high risk of recurrence: long-term results. Urol Int 61:220\u2013226","journal-title":"Urol Int"},{"key":"617_CR48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstrom","year":"2009","unstructured":"Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56:247\u2013256","journal-title":"Eur Urol"},{"key":"617_CR49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000273461","volume":"84","author":"M Porena","year":"2010","unstructured":"Porena M, Del Zingaro M, Lazzeri M, Mearini L, Giannantoni A, Bini V, Costantini E (2010) Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int 84:23\u201327","journal-title":"Urol Int"},{"key":"617_CR50","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.juro.2008.06.034","volume":"180","author":"RK Berglund","year":"2008","unstructured":"Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM (2008) An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J Urol 180:1297\u20131300","journal-title":"J Urol"},{"key":"617_CR51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A Bohle","year":"2003","unstructured":"Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90\u201395","journal-title":"J Urol"},{"key":"617_CR52","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","volume":"55","author":"S Gudjonsson","year":"2009","unstructured":"Gudjonsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, Richthoff J, Hagberg G, Grabe M, Bendahl PO (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55:773\u2013780","journal-title":"Eur Urol"},{"key":"617_CR53","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","volume":"67","author":"RF Han","year":"2006","unstructured":"Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67:1216\u20131223","journal-title":"Urology"},{"key":"617_CR54","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.eururo.2007.12.033","volume":"53","author":"K Hendricksen","year":"2008","unstructured":"Hendricksen K, Witjes WP, Idema JG, Kums JJ, van Vierssen Trip OB, de Bruin MJ, Vergunst H, Caris CT, Janzing-Pastors MH, Witjes JA (2008) Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 53:984\u2013991","journal-title":"Eur Urol"},{"key":"617_CR55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0302-2838(02)00260-9","volume":"42","author":"E Kaasinen","year":"2002","unstructured":"Kaasinen E, Rintala E, Hellstrom P, Viitanen J, Juusela H, Rajala P, Korhonen H, Liukkonen T (2002) Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42:167\u2013174","journal-title":"Eur Urol"},{"key":"617_CR56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2009.06.112","volume":"75","author":"MA Laudano","year":"2010","unstructured":"Laudano MA, Barlow LJ, Murphy AM, Petrylak DP, Desai M, Benson MC, McKiernan JM (2010) Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 75:134\u2013137","journal-title":"Urology"},{"key":"617_CR57","first-page":"944","volume":"7","author":"B Leblanc","year":"2000","unstructured":"Leblanc B, Duclos AJ, Benard F, Valiquette L, Paquin JM, Lapointe S, Mauffette F, Pharand D, Faucher R, Drouin G (2000) Long term follow-up of intravesical Bacillus Calmette-Guerin for the treatment of bladder transitional cell carcinoma. Can J Urol 7:944\u2013948","journal-title":"Can J Urol"},{"key":"617_CR58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","volume":"27","author":"SP Lerner","year":"2009","unstructured":"Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED (2009) Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 27:155\u2013159","journal-title":"Urol Oncol"},{"key":"617_CR59","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","volume":"89","author":"JA Martinez-Pineiro","year":"2002","unstructured":"Martinez-Pineiro JA, Flores N, Isorna S, Solsona E, Sebastian JL, Pertusa C, Rioja LA, Martinez-Pineiro L, Vela R, Camacho JE (2002) Long-term follow-up of a randomized prospective trial comparing a standard 81\u00a0mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27\u00a0mg in superficial bladder cancer. BJU Int 89:671\u2013680","journal-title":"BJU Int"},{"key":"617_CR60","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1442-2042.2008.02146.x","volume":"15","author":"T Okamura","year":"2008","unstructured":"Okamura T, Akita H, Imura M, Kaneko T, Mizuno K, Tozawa K, Kohri K (2008) Efficacy of bacillus Calmette-Guerin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment. Int J Urol 15:976\u2013980","journal-title":"Int J Urol"},{"key":"617_CR61","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jjco\/hye114","volume":"31","author":"S Ozono","year":"2001","unstructured":"Ozono S, Hinotsu S, Tabata S, Takashima K, Fujimoto K, Okajima E, Hirao Y, Ohashi Y, Akaza H, Fukushima S (2001) Treated natural history of superficial bladder cancer. Jpn J Clin Oncol 31:536\u2013540","journal-title":"Jpn J Clin Oncol"},{"key":"617_CR62","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","volume":"165","author":"J Palou","year":"2001","unstructured":"Palou J, Laguna P, Millan-Rodriguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodriguez J (2001) Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and\/or high grade bladder tumors. J Urol 165:1488\u20131491","journal-title":"J Urol"},{"key":"617_CR63","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","volume":"59","author":"V Pansadoro","year":"2002","unstructured":"Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN (2002) Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 59:227\u2013231","journal-title":"Urology"},{"key":"617_CR64","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","volume":"177","author":"GV Raj","year":"2007","unstructured":"Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, Dalbagni G (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177:1283\u20131286","journal-title":"J Urol"},{"key":"617_CR65","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00345-009-0502-1","volume":"28","author":"T Saika","year":"2010","unstructured":"Saika T, Tsushima T, Nasu Y, Miyaji Y, Saegusa M, Takeda K, Kumon H (2010) Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study. World J Urol 28:413\u2013418","journal-title":"World J Urol"},{"key":"617_CR66","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1464-410X.2009.09153.x","volume":"106","author":"V Serretta","year":"2010","unstructured":"Serretta V, Morgia G, Altieri V, Di Lallo A, Ruggiero G, Salzano L, Battaglia M, Falsaperla M, Zito A, Sblendorio D (2010) A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. BJU Int 106:212\u2013217","journal-title":"BJU Int"},{"key":"617_CR67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1442-2042.1997.tb00160.x","volume":"4","author":"T Shinka","year":"1997","unstructured":"Shinka T, Matsumoto M, Ogura H, Hirano A, Ohkawa T (1997) Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guerin: a long-term follow-up. Int J Urol 4:139\u2013143","journal-title":"Int J Urol"},{"key":"617_CR68","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-5347(01)61606-9","volume":"161","author":"E Solsona","year":"1999","unstructured":"Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R (1999) Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161:1120\u20131123","journal-title":"J Urol"},{"key":"617_CR69","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"AP Meijden van der","year":"2001","unstructured":"van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R (2001) Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 166:476\u2013481","journal-title":"J Urol"},{"key":"617_CR70","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/07357900500524405","volume":"24","author":"B Liu","year":"2006","unstructured":"Liu B, Wang Z, Chen B, Yu J, Zhang P, Ding Q, Zhang Y (2006) Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes. Cancer Invest 24:160\u2013163","journal-title":"Cancer Invest"},{"key":"617_CR71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1007199932271","volume":"32","author":"B Altay","year":"2000","unstructured":"Altay B, Girgin C, Kefi A, Cikili N (2000) The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities? Int Urol Nephrol 32:53\u201358","journal-title":"Int Urol Nephrol"},{"key":"617_CR72","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1590\/S1677-55382005000300003","volume":"31","author":"CW Cheng","year":"2005","unstructured":"Cheng CW, Chan PS, Chan LW, Chan CK, Ng CF, Lai MM (2005) 17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer. Int Braz J Urol 31:204\u2013211","journal-title":"Int Braz J Urol"},{"key":"617_CR73","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)36724-1","volume":"148","author":"M Cookson","year":"1992","unstructured":"Cookson M, Sarosdy MF (1992) Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 148:797\u2013801","journal-title":"J Urol"},{"key":"617_CR74","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(01)01539-4","volume":"59","author":"F Iori","year":"2002","unstructured":"Iori F, Di Seri M, De Nunzio C, Leonardo C, Franco G, Spalletta B, Laurenti C (2002) Long-term maintenance bacille Calmette-Guerin therapy in high-grade superficial bladder cancer. Urology 59:414\u2013418","journal-title":"Urology"},{"key":"617_CR75","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"R Jarvinen","year":"2009","unstructured":"Jarvinen R, Kaasinen E, Sankila A, Rintala E (2009) Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 56:260\u2013265","journal-title":"Eur Urol"},{"key":"617_CR76","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)67973-6","volume":"163","author":"T Lebret","year":"2000","unstructured":"Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H (2000) Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol 163:63\u201367","journal-title":"J Urol"},{"key":"617_CR77","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.urology.2009.09.088","volume":"75","author":"K Matsumoto","year":"2010","unstructured":"Matsumoto K, Kikuchi E, Horiguchi Y, Tanaka N, Miyajima A, Nakagawa K, Nakashima J, Oya M (2010) Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods. Urology 75:1385\u20131390","journal-title":"Urology"},{"key":"617_CR78","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/j.1442-2042.2006.01562.x","volume":"13","author":"I Sakai","year":"2006","unstructured":"Sakai I, Miyake H, Harada K, Hara I, Inoue TA, Fujisawa M (2006) Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ. Int J Urol 13:1389\u20131392","journal-title":"Int J Urol"},{"key":"617_CR79","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","volume":"167","author":"TR Griffiths","year":"2002","unstructured":"Griffiths TR, Charlton M, Neal DE, Powell PH (2002) Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 167:2408\u20132412","journal-title":"J Urol"},{"key":"617_CR80","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-5347(01)69072-4","volume":"167","author":"JW Davis","year":"2002","unstructured":"Davis JW, Sheth SI, Doviak MJ, Schellhammer PF (2002) Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol 167:494\u2013500","journal-title":"J Urol"},{"key":"617_CR81","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2006.06706.x","volume":"99","author":"T Gardmark","year":"2007","unstructured":"Gardmark T, Jahnson S, Wahlquist R, Wijkstrom H, Malmstrom PU (2007) Analysis of progression and survival after 10\u00a0years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer. BJU Int 99:817\u2013820","journal-title":"BJU Int"},{"key":"617_CR82","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","volume":"63","author":"A Bohle","year":"2004","unstructured":"Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63:682\u2013686","journal-title":"Urology"},{"key":"617_CR83","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/00365590600744238","volume":"40","author":"T Gardmark","year":"2006","unstructured":"Gardmark T, Bladstrom A, Hellsten S, Malmstrom PU, Members of the Swedish National Bladder Cancer R (2006) Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol 40:276\u2013282","journal-title":"Scand J Urol Nephrol"},{"key":"617_CR84","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3816\/CGC.2007.n.021","volume":"5","author":"JH Taylor","year":"2007","unstructured":"Taylor JH, Davis J, Schellhammer P (2007) Long-term follow-up of intravesical bacillus Calmette-Guerin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. Clin Genitourin Cancer 5:386\u2013389","journal-title":"Clin Genitourin Cancer"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-010-0617-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-010-0617-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-010-0617-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T15:46:46Z","timestamp":1559836006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-010-0617-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,28]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1007\/s00345-010-0617-4","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,28]]}}}